Member Profile
Formosa Laboratories
- C.Y. Cheng
- 1995/12/29
- 4746
- USD 257,691,350.0
- +886-3-324-0895
- 36 Hoping Street, Louchu, Taoyuan, Taiwan
- Immunology
- Infections and Infectious Diseases
- Neuroscience
- Oncology
- Pulmonary/Respiratory Diseases
- Small Molecule Drugs
- Biologics
- Biosimilars
- Vaccines
2015 Taipei Biotech Award, Go-Global Award, Silver Medal
2014 Taipei Biotech Award, Technology Commercialization Award, Silver Medal
2011 Taipei Biotech Award, Technology Commercialization Award, Silver Medal
2009 Taipei Biotech Award, Technology Commercialization Award, Gold Medal
2009 Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Awards, Gold Medal
- Calcipotriol Monohydrate
- Sevelamer Carbonate
- Linezolid
Formosa Laboratories Inc. was founded in Taiwan since 1995, and started with API business and has been serving customers worldwide. As an established API manufacturer receiving GMP inspections from regulatory authorities around the world, we also provide CDMO service extending from APIs and ADCs (Antibody Drug Conjugates) to cytotoxic and non-cytotoxic injectables of aseptic liquid filling and lyophilization. Formosa Laboratories is able to offer full-service GMP manufacturing for drug substance, ADCs and drug product with its API and injectable facilities that accommodates small molecules, biologics and ADCs from pilot scale to commercial scale, all under regulated or cytotoxic control and GMP compliance.
Company Milestones
| 2013 | Passed joint GMP inspection by EDQM and BGC Hamburg |
| 2010 | Passed 1st PAI for Mycophenolate Mofetil by COFEPRIS of Mexico |
| 2009 | Passed 1st PAI for Gadodiamide by PMDA of Japan |
| 2007 | Passed 1st GMP inspection by BSG of Hamburg, Germany |
| 2004 | Passed 1st PAI by US FDA for Leflunomide API |